Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04169711 · ClinicalTrials.gov registry record · Phase 1

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

A Phase 1 study of Clear Cell Renal Cell Carcinoma, sponsored by Arrowhead Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
5
Study locations

NCT04169711: Completed Phase 1 study of Clear Cell Renal Cell Carcinoma, sponsored by Arrowhead Pharmaceuticals.

NCT04169711 is a Phase 1 study of Clear Cell Renal Cell Carcinoma that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 26 participants, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04169711, a Phase 1 study of Clear Cell Renal Cell Carcinoma, has completed, sponsored by Arrowhead Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).

Conditions Studied

Clear Cell Renal Cell Carcinoma

Interventions

  • DRUG ARO-HIF2

Study Locations (5)

Texas

  • Research Site 5 - Dallas
  • Research Site 6 - Houston

Colorado

  • Research Site 1 - Aurora

Nevada

  • Research Site 2 - Las Vegas

Tennessee

  • Research Site 4 - Nashville

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2020-08-17
Est. Completion 2022-07-22
Phase Phase 1
Arrowhead Pharmaceuticals

15 total trials

What the finished NCT04169711 record still lists

NCT04169711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ARO-HIF2 is the first listed.

NCT04169711 lists 5 locations in 4 states (Texas, Colorado, Nevada).

Frequently Asked Questions

What is clinical trial NCT04169711 about?

NCT04169711 is a clinical study titled "Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma". The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).

What is the current status of trial NCT04169711?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2020-08-17. Estimated completion is 2022-07-22.

What conditions does trial NCT04169711 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma.

What interventions are being tested in trial NCT04169711?

The interventions under investigation include: ARO-HIF2 (DRUG).

Who is sponsoring clinical trial NCT04169711?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04169711 being conducted?

This trial has 5 study locations across Colorado, Nevada, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04169711's enrollment target sits among peer trials

26 39th of 45 higher than 7 of 45 other Clear Cell Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04169711, the US trial registry maintained by the National Library of Medicine. NCT04169711 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.